BridgeBio 製藥公司
DE ˙ MUN ˙ US10806X1028
€56.19 ↓ -1.02 (-1.78%)
2026-06-01
分享價格
SecurityDE:2CL / BridgeBio Pharma, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership1,403,642 shares
Latest Disclosed Value $ 104,234,454
Northern Trust Corp reports 4.22% increase in ownership of 2CL / BridgeBio Pharma, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 1,403,642 shares of BridgeBio Pharma, Inc. (DE:2CL) valued at $88,204,863 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,346,754 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 4.22% during the quarter. The current value of the position is $78,870,644 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,403,642 56,888 4.22 104,234 1.19 0.0028
2026-02-17 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,346,754 -55,655 -3.97 103,013 41.42 0.0027
2025-11-14 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,402,409 38,726 2.84 72,841 23.70 0.0021
2025-08-13 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,363,683 76,836 5.97 58,884 32.36 0.0081
2025-05-13 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,286,847 -36,411 -2.75 44,486 22.52 0.0066
2025-02-14 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,323,258 43,955 3.44 36,310 11.48 0.0051
2024-11-13 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,279,303 150,284 13.31 32,571 13.89 0.0053
2024-08-14 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,129,019 -190 -0.02 28,598 -18.09 0.0048
2024-05-14 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,129,209 -25,763 -2.23 34,915 -25.12 0.0060
2024-02-13 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,154,972 1,057 0.09 46,626 53.23 0.0084
2023-11-13 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,153,915 24,643 2.18 30,429 56.66 0.0059
2023-08-11 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,129,272 171,915 17.96 19,423 22.37 0.0037
2023-05-15 2023-03-31 13F BRIDGEBIO PHARMA COM 10806X102 957,357 16,189 1.72 15,873 121.34 0.0031
2023-02-13 2022-12-31 13F BRIDGEBIO PHARMA COM 10806X102 941,168 5,130 0.55 7,172 -22.93 0.0015
2022-11-14 2022-09-30 13F BRIDGEBIO PHARMA COM 10806X102 936,038 -30,513 -3.16 9,305 6.03 0.0021
2022-08-12 2022-06-30 13F BRIDGEBIO PHARMA COM 10806X102 966,551 -30,739 -3.08 8,776 -13.31 0.0019
2022-05-13 2022-03-31 13F BRIDGEBIO PHARMA COM 10806X102 997,290 -14,478 -1.43 10,123 -40.02 0.0018
2022-02-08 2021-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,011,768 -103,631 -9.29 16,877 -67.72 0.0028
2021-11-15 2021-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,115,399 37,336 3.46 52,279 -20.45 0.0093
2021-08-13 2021-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,078,063 49,053 4.77 65,719 3.68 0.0116
2021-05-12 2021-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,029,010 196,174 23.55 63,387 7.03 0.0118
2021-02-11 2020-12-31 13F BRIDGEBIO PHARMA COM 10806X102 832,836 -19,704 -2.31 59,222 85.14 0.0115
2020-11-16 2020-09-30 13F BRIDGEBIO PHARMA COM 10806X102 852,540 62,103 7.86 31,988 24.10 0.0070
2020-08-14 2020-06-30 13F BRIDGEBIO PHARMA COM 10806X102 790,437 8,455 1.08 25,776 13.67 0.0061
2020-05-14 2020-03-31 13F BRIDGEBIO PHARMA COM 10806X102 781,982 474,058 153.95 22,677 110.13 0.0065
2020-02-14 2019-12-31 13F BRIDGEBIO PHARMA COM 10806X102 307,924 9,033 3.02 10,792 68.15 0.0024
2019-11-13 2019-09-30 13F BRIDGEBIO PHARMA COM 10806X102 298,891 298,891 6,418 0.0015
2019-08-13 2019-06-30 13F BRIDGEBIO PHARMA COM 10806X102 0 0 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.